Revvity Inc vs Sprott Uranium Miners ETF — how do they compare? Revvity Inc trades at $110.7 (market cap $11.87B), while Sprott Uranium Miners ETF trades at $50.32. The key difference: Revvity Inc pays a 0.26% dividend while Sprott Uranium Miners ETF pays none, and Revvity Inc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| RVTY | URNM | |
|---|---|---|
Market Cap | $11.87B | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $117.75 | $83.99 |
52-Week Low | $82.26 | $44.14 |
Enterprise Value | $14.36B | — |
Dividend Yield | 0.26% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.
The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.
URNM trades at $48.25, up 0.06% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The ETF focuses on uranium miners, benefiting from rising nuclear energy demand driven by AI power needs. Recent news highlights strong performance, with URNM up 26% year-to-date as of April 2026, though some articles question miner valuations versus uranium prices.
The outlook for URNM is supported by long-term nuclear energy growth, but risks include volatility in uranium prices and concentrated miner exposure. Analyst sentiment is mixed, with some seeing upside from AI-driven power demand, while others caution on supply chain gaps and equity optimism diverging from fundamentals.
Trailing returns across standard periods
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →